https://www.live-feeds.com/feed/after-10-9b-exit-to-abbvie-apogee-execs-join-paragon-to-scale-its-r-d-company-creation-engineContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/after-10-9b-exit-to-abbvie-apogee-execs-join-paragon-to-scale-its-r-d-company-creation-enginehttps://www.live-feeds.com/feed/after-10-9b-exit-to-abbvie-apogee-execs-join-paragon-to-scale-its-r-d-company-creation-engine#u136296Mon, 19 Oct 2026 15:15:55 +0000Biotechnology firm Paragon Labs has brought in the former senior leadership team of Apogee Therapeutics following AbbVie's acquisition of Apogee. The new executives include CEO Michael Henderson, Head of R&D Carl Dambkowski, Chief Business and Financial Officer Dan Mulreany, Chief Legal Officer Matt Batters, and Chief People Officer Emily Cox. The team will oversee the advancement of Paragon-discovered drug candidates into clinical development and build new biotechnology companies around promising therapeutic assets, beginning with Velaris Therapeutics.Why it mattersThe executive tran